These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12888171)

  • 1. [Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children].
    Pautard B; Hachulla E; Bagot d'Arc M; Chantreuil L
    Rev Med Interne; 2003 Aug; 24(8):505-13. PubMed ID: 12888171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
    Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
    Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A; Bauer M; Kremer S
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Genereau T; Simon A; Maisonobe T; Eymard B; Herson S
    Arthritis Rheum; 2002 Feb; 46(2):467-74. PubMed ID: 11840450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.
    Eijkhout HW; van Der Meer JW; Kallenberg CG; Weening RS; van Dissel JT; Sanders LA; Strengers PF; Nienhuis H; Schellekens PT;
    Ann Intern Med; 2001 Aug; 135(3):165-74. PubMed ID: 11487483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacovigilance study of a regional intravenous immunoglobulin].
    Sisti AM; Mahieu AC; Manfredi MJ
    Allergol Immunopathol (Madr); 2004; 32(6):326-33. PubMed ID: 15617659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
    Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
    J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous immunoglobulin in the treatment of malignant epilepsy in children].
    Sterio M; Gebauer E; Vucicević G; Zalisevskij G; Felle D; Kolarov N
    Wien Klin Wochenschr; 1990 Apr; 102(8):230-3. PubMed ID: 2111611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product.
    Stiehm ER; Casillas AM; Finkelstein JZ; Gallagher KT; Groncy PM; Kobayashi RH; Oleske JM; Roberts RL; Sandberg ET; Wakim ME
    J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):848-9. PubMed ID: 9648714
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
    Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
    Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
    Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
    J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.
    Moy JN; Scharenberg AM; Stein MR; Suez D; Roberts RL; Levy RJ; Ballow M; Fasano MB; Dash CH; Leach SJ
    Clin Exp Immunol; 2010 Dec; 162(3):510-5. PubMed ID: 21070209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
    Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M
    J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.